Dapagliflozin Ameliorate Type-2 Diabetes Associated Neuropathy via Regulation of IGF-1R Signaling
Authors:
- 3 April 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 20 (1) , 1-21
Abstract
Dapagliflozin, an approved SGLT2 inhibitor, has been shown to have extra-glycemic effects like cardio-reno protection. However, the neuroprotective effects of SGLT2 inhibitors against diabetic neuropathy (DN) have not been explored. The current study aimed to determine the neuroprotective potential of Dapagliflozin against STZ-NAD-induced DN in Wistar rats via IGF-1 signaling. DN was induced by STZ-NAD in male Wistar rats. After 60 days of induction, behavioural tests were conducted to access DN, and treatment with Dapagliflozin (0.75 mg/kg & 1.50 mg/kg) was initiated for 30 days. At the end of the study, the brain and sciatic nerve were isolated and expression analysis of IGF-1R signaling molecules was carried out using western blotting, qRTPCR, and immunohistochemistry. Structural changes in the brain and sciatic nerve were ascertained by histopathology. The results showed that treatment with Dapagliflozin improved behavioural parameters in STZ-NAD-induced DN rats. The decreased expression levels of IGF1R signaling pathway molecules and increased expression of p-AKT were found to increase and decrease in the brain and sciatic nerve, respectively after the treatment. Histological studies demonstrated the restoration of normal architecture of the brain and sciatic nerve after treatment with dapagliflozin. The altered expression of IGF-1R signaling molecules established the neuroprotective potential of dapagliflozin against DN.Keywords
This publication has 77 references indexed in Scilit:
- Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathyFitoterapia, 2012
- Antidiabetic and antioxidant potential of β-sitosterol in streptozotocin-induced experimental hyperglycemiaJournal of Diabetes, 2011
- Animal models of neuropathic painFundamental & Clinical Pharmacology, 2011
- Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetesDiabetes Therapy, 2010
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic RatsDiabetes, 2008
- Signaling by insulin-like growth factor 1 in brainEuropean Journal of Pharmacology, 2004
- The IGF-1/Akt Pathway Is Neuroprotective in Huntington's Disease and Involves Huntingtin Phosphorylation by AktDevelopmental Cell, 2002
- Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory painPain, 1996
- Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic painPain, 1993
- Long-Term Diabetogenic Effect of Streptozotocin in RatsPancreas, 1993